On September 21, 2021, the Ukrainian parliament adopted a bill that allows the purchase of innovative medicines at the expense of the state budget under managed entry agreements.

The concept of managed entry agreements (MEAs) appeared in Ukrainian legislation in 2020.

This procedure should provide patients with innovative drugs that do not have generic drugs, in particular in the treatment of severe chronic diseases – oncology, hematology, rare pathologies, the use of assisted reproductive technologies.

The deputies made the appropriate amendments to the law on public procurement, excluding the purchase of original (innovative) medicines subject to procurement through the MEA by the end of 2023.

In case of registration in Ukraine of a generic drug with the same international non-proprietary name and indications for use, the managed entry agreements are subject to early termination.

The list of medicines that will be purchased using the MEA must be approved by the Cabinet of Ministers.